SyntheticMR AB publishes financial guidance ahead of the forthcoming rights issue

SyntheticMR preliminarily reports Q4 2025 net revenue of MSEK 18.0 (+43% y/y) and full-year revenue MSEK 57.0 (+2%), while Q4 EBIT was MSEK -5.3 and full-year EBIT worsened to MSEK -49.3 (vs -18.3 prior year) driven by impairment of MSEK -18.5 and acquisition costs of MSEK -0.3 (preliminary adjusted operating loss MSEK -30.5). Cash at year-end was weak at MSEK 7.4, and the company has launched a rights issue of approximately MSEK 32.8 to bolster liquidity; Combinostics contributed MSEK 3.6 in Q4 and MSEK 12.9 for the year, with ARR up to MSEK 11.7 (+38%). Strategic positives include completed Combinostics integration and regulatory approvals for cNeuro/cMRI in Europe and India, but the large impairment, significant full-year loss and low cash balance make the capital raise and execution risks key for investors.

Analysis

Market structure: SyntheticMR’s short-term winners are its recurring‑revenue assets (cNeuro ARR up to MSEK 11.7, +38% YoY) and the Combinostics business (MSEK 12.9 revenue, +41%), which increase stickiness versus one‑off SyMRI research sales that are under pressure in the US. The company’s new European ARIA approval creates a first‑mover advantage into a rapidly expanding anti‑amyloid monitoring market, implying improved pricing power for cMRI services if adoption follows clinical rollouts. Cross‑asset: expect elevated equity volatility for small‑cap Swedish medtech, wider credit spreads for similar vendors, and modest SEK weakness around dilution events; commodity impact is negligible.

Risk assessment: Tail risks include regulatory reversal on ARIA, further impairments (contract assets already MSEK -18.5), or failure of the rights issue to restore runway (cash MSEK 7.4 vs. preliminary FY loss MSEK -49.3). Immediate catalyst windows: rights trading/subscription (20 Jan–3 Feb) and year‑end report on 6 Feb 2026; medium risk window is 3–12 months as US research sales either recover or continue to lag. Hidden dependencies: collectability of contract assets, integration synergies from Combinostics, and dependency on a few large hospital contracts (one MSEK 1/yr, one MSEK 3 over 5 yrs).

Trade implications: Existing holders should prioritize pro‑rata participation in the MSEK 32.8 rights issue to avoid severe dilution given limited cash; new entrants should size positions small (1–2% NAV) and wait for post‑rights transparency (Feb 4–6). If listed options exist, use 3–6 month call spreads to express upside while limiting downside; hedge long exposure with a 1:1 short position in small‑cap medtech beta (e.g., small‑cap healthcare ETF XBI) if systemic risk rises. Reassess after Feb 6: positive confirmation of cash >MSEK 30 and adjusted operating loss close to preliminary MSEK -30.5 warrants scaling in.

Contrarian angles: Consensus may over‑discount the Combinostics ARR lift—41% revenue growth and low churn imply durable recurring revenue that can rapidly improve margins if research sales stabilize. The headline MSEK -49.3 EBIT includes large non‑cash impairments; if future cash burn falls below MSEK 25/quarter post‑rights, equity upside is asymmetric. Conversely, if rights pricing forces heavy dilution (>30% new equity) or US research demand fails to recover by Q3 2026, downside will be severe; buy on >25% post‑rights drawdown with 6–12 month horizon.

Key Decisions for Investors

• Existing SyntheticMR shareholders: participate pro‑rata in the MSEK 32.8 rights issue (subscribe by 3 Feb 2026) to maintain ownership and avoid >30% dilution; allocate capital up to current weight (no more than 2–5% NAV incremental) given cash runway risk.
• New speculative longs: establish 1–2% NAV long position in SyntheticMR after the year‑end report (post 6 Feb 2026) conditional on confirmation cash >MSEK 30 and adjusted FY loss ≤ MSEK -35; set initial stop‑loss at -30% and target 100% return within 12 months.
• Options trade: if options available, buy a 3‑6 month bull call spread sized to 0.5–1.0% NAV (buy near‑ATM call, sell 20–30% OTM) to capture upside from ARIA adoption while capping premium risk; enter after rights settlement (4 Feb 2026).
• Hedge / pair: hedge new long exposure by shorting 0.5–1.0% NAV of the small‑cap biotech ETF XBI (or equivalent) to reduce sector beta until Feb 6 report; unwind hedge if SyntheticMR confirms cash >MSEK 30 and ARR growth continues quarter‑over‑quarter.